ArticleOncology letters2025
Factors influencing pathological complete response to neoadjuvant chemotherapy in resectable breast cancer: A retrospective study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Predictive Value of CT-Derived Skeletal Muscle Metrics for Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.European journal of breast health · 2026Article
- Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database.Journal of surgical oncology · 2026Article
- Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.International journal of breast cancer · 2026Article
- Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy (NAC) is widely used to treat breast cancer and a pathological complete response (pCR) following NAC is associated with an optimal prognosis; however, pCR rates vary significantly. In the present study, the effects of clinicopathological factors and the administration of different taxanes on pCR rates in patients with resectable breast cancer were assessed. A total of 552 patients with breast cancer who received NAC between May 2019 and June 2024 were included in the present study. The clinicopathological traits of the patients were retrieved from medical records and their association with the pCR rate was evaluated using univariate and multivariate regression analyses. The efficacy of nanoparticle albumin-bound (Nab)-paclitaxel, docetaxel and paclitaxel liposomes in different subtypes of breast cancer were further evaluated. A total of 189 of 552 (34.2%) patients achieved pCR following NAC. The pCR rate varied significantly among different molecular subtypes as follows: 58.9% (96/163), 40.7% (37/91), 35.6% (37/104) and 9.8% (19/298) among patients with hormone receptor (HR) negative (-) human epidermal growth factor receptor 2 (HER2) positive (+), HR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.